日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Global Recruiting Patterns and Placebo Response Rates in Clinical Trials of Psoriatic Arthritis and Plaque Psoriasis

银屑病关节炎和斑块状银屑病临床试验的全球招募模式和安慰剂反应率

Kerschbaumer, Andreas; Steiner, Marlene; Khalili, Suzanne; Shehab, Azad; Jordanov, Alexander; Wildner, Brigitte; Maad, Magdalena; Smolen, Josef S; Aletaha, Daniel

Do high rheumatoid factor levels impact response to certolizumab pegol in patients with inadequately controlled rheumatoid arthritis? A post hoc analysis of the phase IIIb REALISTIC trial

高类风湿因子水平是否会影响类风湿关节炎控制不佳患者对赛妥珠单抗的疗效?一项对 IIIb 期 REALISTIC 试验的事后分析

Smolen, Josef S; Mikuls, Ted R; Galloway, James; Müller-Ladner, Ulf; Curtis, Jeffrey R; Hashimoto, Motomu; Takeuchi, Tsutomu; Choy, Ernest; Tanaka, Yoshiya; Cara, Carlos; Lauwerys, Bernard; Tilt, Nicola; Ufuktepe, Baran; Taylor, Peter C

Long-Term Effectiveness of Baricitinib and Other b/tsDMARDs in Patients with Rheumatoid Arthritis with Early Low Disease Activity or Remission: 2-Year Data from the RA-BE-REAL Study

巴瑞替尼和其他生物/靶向合成DMARDs治疗早期低疾病活动度或缓解期类风湿关节炎患者的长期疗效:RA-BE-REAL研究的2年数据

Alten, Rieke; Östör, Andrew; Edwards, Christopher J; Smolen, Josef S; Haladyj, Ewa; Ng, Khai Jing; Ogwu, Samuel; Kaneko, Yuko

Efficacy and Safety of Tofacitinib and Adalimumab in Rheumatoid Arthritis by Body Mass Index-Normalized Methotrexate Dose: A Post Hoc Analysis

按体重指数校正的甲氨蝶呤剂量评估托法替尼和阿达木单抗治疗类风湿性关节炎的疗效和安全性:一项事后分析

Takeuchi, Tsutomu; Tanaka, Yoshiya; Yamanaka, Hisashi; Yamaoka, Kunihiro; Sugiyama, Naonobu; Iikuni, Noriko; Toyoizumi, Shigeyuki; Kwok, Kenneth; Tsai, Wen-Chan; Mysler, Eduardo; Moots, Robert J; Smolen, Josef S; Fleischmann, Roy

Roads to remission: evolving treatment concepts in type 2 inflammatory diseases

通往缓解之路:2型炎症性疾病治疗理念的演变

Lommatzsch, Marek; Blumchen, Katharina; Beck, Lisa A; Bousquet, Jean; Brusselle, Guy G; Fokkens, Wytske J; Hamelmann, Eckard; Lau, Susanne; Ott, Hagen; Pfaar, Oliver; Sampson, Hugh A; Smolen, Josef S; Taube, Christian; Tarner, Ingo H; Wagenmann, Martin; Werfel, Thomas; Worm, Margitta; Renz, Harald

Upadacitinib as monotherapy in patients with rheumatoid arthritis and prior inadequate response to methotrexate: results at 260 weeks from the SELECT-MONOTHERAPY randomised study

乌帕替尼单药治疗既往对甲氨蝶呤反应不足的类风湿性关节炎患者:SELECT-MONOTHERAPY随机研究260周结果

Smolen, Josef S; Emery, Paul; Rigby, William; Tanaka, Yoshiya; Vargas, Juan Ignacio; Jain, Manish; Kato, Koji; Carter, Kyle M; Khan, Nasser; Phillips, Charles; Meerwein, Sebastian; Cohen, Stanley B

Immunoadsorption as a novel therapy for refractory idiopathic inflammatory myopathies: a retrospective observational study

免疫吸附疗法作为难治性特发性炎症性肌病的新疗法:一项回顾性观察研究

Kastrati, Kastriot; Karonitsch, Thomas; Rajab, Hanien; Reindl-Schwaighofer, Roman; Eskandary, Farsad; Pajenda, Sahra; Mrak, Daniel; Heil, Peter Maximilian; Kiener, Hans Peter; Bonelli, Michael; Derfler, Kurt; Aletaha, Daniel; Smolen, Josef S; Radner, Helga

Attitudes of psychiatric staff toward coercion: nationwide AttCo study

精神科工作人员对强制措施的态度:全国性 AttCo 研究

Czernin, Klara; Oster, Anna; Jaeger, Matthias; Junghanss, Julia; Baumgartner, Josef S; Mahler, Lieselotte

Selectivity, efficacy and safety of JAKinibs: new evidence for a still evolving story

JAK抑制剂的选择性、疗效和安全性:仍在发展中的故事的新证据

Bonelli, Michael; Kerschbaumer, Andreas; Kastrati, Kastriot; Ghoreschi, Kamran; Gadina, Massimo; Heinz, Leonhard X; Smolen, Josef S; Aletaha, Daniel; O'Shea, John; Laurence, Arian

Olokizumab plus methotrexate: safety and efficacy over 106 weeks of treatment

奥洛珠单抗联合甲氨蝶呤:106周治疗的安全性和有效性

Feist, Eugen; Fleischmann, Roy M; Fatenejad, Saeed; Bukhanova, Daria; Grishin, Sergey; Kuzkina, Sofia; Luggen, Michael; Nasonov, Evgeniy; Samsonov, Mikhail; Smolen, Josef S